Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Matthew T. Newman"'
Autor:
Matthew T. Newman, Mihir Bikhchandani
Publikováno v:
Cancer Reports, Vol 7, Iss 7, Pp n/a-n/a (2024)
ABSTRACT Background Immune checkpoint inhibitors (ICIs) have led to improved outcomes for many cancer types. However, their use can also precipitate immune‐related adverse events (irAEs) that can affect any organ system. While irAEs are often mild,
Externí odkaz:
https://doaj.org/article/0617a702ca9140ba9334580f8cd1e084
Autor:
Kaycee B. Moshofsky, Hyun J. Cho, Guanming Wu, Kyle A. Romine, Matthew T. Newman, Yoko Kosaka, Shannon K. McWeeney, Evan F. Lind
Publikováno v:
Blood Advances, Vol 3, Iss 20, Pp 3038-3051 (2019)
Abstract: Acute myeloid leukemia (AML) remains difficult to treat due to mutational heterogeneity and the development of resistance to therapy. Targeted agents, such as MEK inhibitors, may be incorporated into treatment; however, the impact of MEK in
Externí odkaz:
https://doaj.org/article/d33dcf95792246069121c242dfdc873d
Autor:
Kyle A. Romine, Kevin MacPherson, Hyun-jun Cho, Yoko Kosaka, Patrick A. Flynn, Kaelan H. Byrd, Jesse L. Coy, Matthew T. Newman, Ravina Pandita, Christopher P. Loo, Jaime Scott, Andrew C. Adey, Evan F. Lind
Publikováno v:
Leukemia. 37:580-592
Many acute myeloid leukemia (AML) patients exhibit hallmarks of immune exhaustion, such as increased myeloid-derived suppressor cells, suppressive regulatory T cells and dysfunctional T cells. Similarly, we have identified the same immune-related fea
Autor:
Matthew T. Newman, Jaime Scott, Evan F. Lind, Jesse L. Coy, Hyun-jun Cho, Kaelan Byrd, Christopher P. Loo, Kyle A. Romine, Patrick A. Flynn, Yoko Kosaka
Many acute myeloid leukemia (AML) patients exhibit hallmarks of immune exhaustion, such as increased myeloid derived suppressor cells (MDSCs), suppressive regulatory T cells (Tregs) and dysfunctional T cells. We have developed a mouse model of AML dr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94e20a348eca2dc8dca0a80900b7efe7
https://doi.org/10.1101/2021.08.04.455147
https://doi.org/10.1101/2021.08.04.455147
Autor:
Yoko Kosaka, Matthew T. Newman, Kyle A. Romine, Patrick J. Flynn, Jesse L. Coy, Evan F. Lind, Christopher P. Loo, Kaelan Byrd, Hyun-jun Cho
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundAcute Myeloid Leukemia (AML) is the most common adult leukemia and has a very poor prognosis. With a 5-year survival of under 30% (seer.cancer.gov), most people diagnosed with AML will die from the disease. AML is caused by an uncontrolled
Autor:
Kyle Alexander Romine, Hyun-jun Cho, Yoko Kosaka, Patrick Flynn, Kaelan H Byrd, Jesse L Coy, Matthew T Newman, Jaime Scott, Christopher Loo, Evan F Lind
Publikováno v:
The Journal of Immunology. 208:122.15-122.15
Acute Myeloid Leukemia (AML) is the most common adult leukemia and has a 5-year survival of under 30%. AML is caused by uncontrolled proliferation of myeloid cells resulting from a combination of mutations that affect proliferation, differentiation a
Autor:
Sunil K. Joshi, Daniel Bottomly, Brian J. Druker, Matthew T. Newman, Shannon K. McWeeney, Elie Traer, Evan F. Lind
Publikováno v:
Journal of Clinical Oncology. 39:7020-7020
7020 Background: The advent of genomic sequencing technologies has revealed underlying genetic alterations, such as FLT3 mutations, that can be targeted in acute myeloid leukemia (AML). However, development of resistance limits the durability of resp
Autor:
Kaycee B. Moshofsky, Hyun J. Cho, Yoko Kosaka, Matthew T. Newman, Jeffrey W. Tyner, Evan F. Lind
Publikováno v:
Cancer Research. 79:508-508
Although most patients with acute myeloid leukemia (AML) respond to standard of care chemotherapy, the majority of patients will relapse, and the 5-year overall survival rate persists at 25%. The high rates of relapse and poor survival have contribut
Autor:
Bill H. Chang, Jessica Leonard, Jeffrey W. Tyner, Yoko Kosaka, Brian J. Druker, Evan F. Lind, Matthew T. Newman, Adam J. Lamble, Pavani Malla
Publikováno v:
Blood. 132:1547-1547
Introduction: Blinatumomab is a bispecific antibody approved for the use in adults with relapsed acute lymphoblastic leukemia (ALL) but only about 50% of patients respond. A few brief reports have suggested that differences in T cell subsets between
Autor:
Matthew T. Newman, John F. Conley, Robin Ekeya, Shree C. Aier, Evan F. Lind, Dustin Z. Austin, Lampert Lester, Kavita Meduri, Jun Jiao, Patrick Crawford
Publikováno v:
Microscopy and Microanalysis. 23:1292-1293